Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IxCell hUC-MSC-P in SSc-ILD
NCT06823063Phase 1Not yet recruiting
- Sponsor
- iXCells Biotechnologies
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IxCell human umbilical cord mesenchymal stem cells in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (3 arms), sponsored by iXCells Biotechnologies. Primary endpoints: Adverse Events at 24 weeks and Forced Vital Capacity at 24 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
IxCell human umbilical cord mesenchymal stem cells
03
Conditions
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Beyond the preview
Go deeper on NCT06823063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823063.